Optimal Use of Sandimmun in Endogenous Uveitis

Due to the largely disappointing therapeutic and sight Ensuing from the above observations, the following guidelines are suggested: saving results achieved so far with conventional therapy using systemic corticosteroids and cytotoxic agents, new treatment modalities have been sought. a) Start treatment with Sandimmun at initial doses of During the last four years, a total of over 300 patients 5 mg/kg/day. b) Use Sandimmun in combination with low dose sys suffering from endogenous intermediate and posterior temic corticosteroids if necessary, in order to uveitis, including more than 150 with Beh̃et's disease achieve remission. involving the posterior segment of the eye, were treated with Sandimmun. The initial dose ranged from 5 to c) Use Sandimmun doses higher than 5 mg/kg/day on 10 mg/kg/day. These patients were treated openly with ly when absolutely indicated. Sandimmun in 11 independent studies all over the d) Taper Sandimmun dose as rapidly as possible to a world (over 200 patients) and in a masked manner in 4 maintenance dose below 5 mg/kg/day. e) Do not discontinue treatment with Sandimmun rap independent controlled studies (over 100 patients re idly.